IL2 and neoplasm: The humanized immunocytokine hu14.18-IL2 was designed to selectively target malignancies and concentrate human IL2 at the tumor site by fusing human IL2 to the heavy chains of the intact humanized form of an anti-GD2 monoclonal antibody [35].